RET and medullary thyroid gland carcinoma: When a germline mutation is found, all first-degree relatives should be submitted to RET analysis to distinguish “gene carriers” from “nongene carriers.” The RET gene carriers are at very high risk to develop MTC and they must be submitted to a diagnostic and therapeutic strategy which is very much conditioned by the ATA level of risk of the mutation.